Dr. Mark A. Schuster, Founding Dean and CEO of Kaiser Permanente’s Bernard J. Tyson School of Medicine, will be speaking before the Pasadena Rotary Club during its weekly meeting on Wednesday, February 19.
He will be introduced by Phil Hawkey. The meeting is open to the public and no RSVP is required.
Dr. Schuster became the founding dean and CEO of the new Kaiser Permanente School of Medicine in October 2017. Prior to that, he had served as the William Berenberg Professor of Pediatrics at Harvard Medical School and chief of general pediatrics and vice chair for health policy in the Department of Medicine at Boston Children’s Hospital since 2007.
Dr. Schuster is internationally recognized as a leader in research on child, adolescent, and family health. With funding from the National Institutes of Health (NIH), Centers for Disease Control (CDC), and the Agency for Healthcare Research and Quality (AHRQ), he has studied topics such as quality of care, health disparities, family leave, HIV prevention, obesity prevention, sexual and gender minority health, and adolescent sexual health.
Before moving to Boston, he served as professor of pediatrics and health services at UCLA Schools of Medicine and Public Health and director of health promotion and disease prevention at RAND, the Santa Monica think tank.
Dr. Schuster has co-authored over 250 articles and two books. He is an elected member of the National Academy of Medicine and has served as president of the Academic Pediatric Association. He is a recipient of the Richardson Award for lifetime achievement from the Society for Pediatric Research, the Barger Excellence in Mentoring Award from Harvard Medical School, and the Joseph St. Geme, Jr., Award for leadership in pediatrics from the Federation of Pediatric Organizations.
Dr. Schuster was named among Modern Healthcare’s 100 Most Influential People in Healthcare for 2018 and 2019 and among Modern Healthcare’s 50 Most Influential Clinical Executives in 2019.
He received his BA summa cum laude from Yale, his MD from Harvard Medical School, his MPP from the Harvard Kennedy School of Government, and his PhD from the Pardee RAND Graduate School. He completed his pediatric residency at Boston Children’s Hospital and his fellowship at the UCLA Robert Wood Johnson Clinical Scholars Program.
The Pasadena Rotary Club meets every Wednesday at lunchtime at the University Club of Pasadena, located at 175 N. Oakland Ave.
Buffet lunch during the Rotary Club meeting is $33 and includes complimentary valet parking.
For more information, email email@example.com.
The building at 493-497 E. Colorado Blvd. in Pasadena has been sold for more than the asking price, according to Corey Harper of Coldwell Banker Commercial, who represented the seller.
“Yes, we sold the building for $2.9 million to an owner/user that will be operating their antique shop (Royal Antiques),” Harper said. “They are doing renovations at this time.”
The new owners – Arash (Anthony) Akmal and Helia Samadi – are the husband-and-wife team that operates Royal Antiques, located at 446 S. Fair Oaks Ave. in Pasadena.
Harper said the new owners purchased the property from Bob and Arlene Oltman, the former owners and operators of the Pasadena Museum of California Art.
The property was listed on LoopNet.com as a retail-type Class C building with 8,998 square feet of gross leasable area, on a 0.13-acre lot.
It was built in 1949, according to the listing.
Currently, Messerian Oriental Rugs is leasing 3,248 square feet of the space, with the lease ending in March 2023.
Michelin-trained chef Dean Yasharian (Chateau Marmont, Bar Boulud at the Mandarin Oriental Hotel London, Restaurant Daniel, Restaurant Gordon Ramsay, Midsummer House) brings his extensive classic French and modern farm-to-table training to Old Pasadena with his first restaurant, Perle, set to open in March 2020.
Perle will offer a sustainable and organic-focused menu featuring classic French dishes as well as modern, seasonal creations influenced by California’s fresh cuisine. Yasharian employs a mirrored menu concept, with half of the menu consisting of meat and seafood dishes and the other half composed of vegetarian and plant-based dishes. The menu will be updated weekly with new items.
Yasharian attributes his hard work ethic and love for country style cooking for the Perle menu from his extensive farming heritage in the Northeast, where his father is still a sustainable organic livestock and crop farmer. The menu will also incorporate touches of international cuisines such as Armenian and Persian, which are inspirations to Chef Yasharian.
Dishes on the meat and seafood menu may include organic coq au vin with tahdig rice, grass-fed steak tartare and Santa Barbara ridgeback prawns with salt-cured Meyer lemon and saffron. The vegetarian and vegan menu will feature vegan French onion soup with cashew cheese gratin, frisée Lyonnaise salad with tofu “egg” and tempeh “bacon lardons,” and braised Le Puy green lentils with plant-based sausage and Dijon.
“I couldn’t be more excited to open my first restaurant in the community where my family and I live,” says Yasharian. “I am overjoyed to share my experiences and passion for food, wine and hospitality with new friends, old friends and family. This project is very special to my family, as Perle is named after our eldest daughter, Luna Pearl, whose beautiful life has brought much inspiration and motivation to my work.”
Not only is Yasharian the chef and owner of Perle, but he and his family have also executed much of the interior design, from handcrafting the mahogany tables to painting the kitchen. Perle’s timeless aesthetic lets the building’s historical integrity shine, with traditional decorative ceiling beams, a carved wooden bar, rattan chairs, antique mirrors and vintage art.
Perle will open for dinner with a beer and wine menu to start from 5:30 p.m. to 10:30 p.m. Tuesday through Thursday and 5:30 p.m to 11:30 p.m. Friday and Saturday with weekend brunch to launch in the coming months. Prices for the dishes range from $10 to $32. Perle is located at 43 Union St. in Pasadena, California.
“There are no secrets, only strategies,” said realtor Allie Altschuler Wednesday, before a group meeting of would-be home buyers and real estate agents.
Altschuler and realtor Steve Clark’s Clarkliving team from Compass Real Estate presented the informal chat, “Building Your Future Together: A Valentine’s Guide to Buying a Home,” over snacks and Valentine’s candy, in the company’s spacious offices above Colorado Boulevard, in the Playhouse District.
The company serves a large and busy Pasadena market, but also markets homes in Northeast LA.
“As we’ve been meeting, here in the office,” said Altschuler, before the presentation, “We’ve all been hearing the same issues and questions and concerns. We thought this would be a good way to answer a lot of those at once.”
Clark, who leads the team, noted right off the bat that oftentimes, real estate agents bring out the skeptic in every home buyer.
“When I first started in this business,” said Clark, “I was really surprised at how low the moral bar was set for this industry. It was just people in it for the money. They have no skin in the game.”
Real estate is lucrative, to be sure, but as Clark and Altschuler pointed out, the right real estate agent can truly make all the difference in your home sale.
Both Clark and Altschuler noted the current trend towards off-market home sales. That is, homes that might be owned by a seller who wishes to be discreet, or has a deal they know will take off, the moment it is announced.
“Everyone wants those deals,” said Altschuler, “but they come and go fast. You might never see them.”
Clark also pointed out that in an off-market sale, the buyer may actually end up paying more than the market would have offered, because of the excitement surrounding the sale.
“A seller may say, ‘We were going to put this on the market next week for $900k,’ said Clark, ‘but if you want it, you can pick it up for $1 million,’ and you end up paying more for it.”
But Clarkliving agent April Kass told the group that it doesn’t always go that way since the competition can be unpredictable.
“There are still gems out there,” she said.
Clark also showed trepidation about buying through online platforms where buyers miss out on developing a relationship with a human agent.”
The same goes for discount brokerages (you know the ones, they said) who cannot provide the same intangibles that a more qualified realtor can.
Said Altschuler, “I always remind buyers to ask a realtor they’re trying to vet, ‘Is this your full time job?’ It’s a concise question that will quickly tell you a lot about the person you’re dealing with.” And, she added, the familiar adage, “If what they’re offering you sounds too good to be true…” Clark agreed, saying, “Our bottom line is “Can we help the client?”
The team also stressed that home buying is a business of minutes, and that buyers should expect their agents to understand that as well. A realtor who doesn’t return emails for three days, might have the same attitude towards a mortgage broker, for example, and that could hurt your chance on a great deal happening right at this moment.
Buyers should be less concerned with how long an agent has been in the business, and more concerned about how many transactions they’ve been involved in. An agent who’s been working for 20 years doing one deal per year isn’t likely to be as savvy as an agent who’s been working for three years and does 20+ deals per year.
Many agents come off well at first, but experience counts, as in any other field.
In regards to being financially ready, buyers should also do their own homework, said Clark.
“You may be test driving a BMW, only to find out that you only qualify to buy a Honda,” he said, noting that there’s nothing wrong with a Honda, but it’s better to have a clear idea of your buying power before you go out and fall in love.
Choosing the right agent can also be as easy as having the right recommendations, said Clark.
“Talk to anyone who has worked with them before,” said Clark. “That goes for mortgage brokers, and other agents and other buyers. Those recommendations will be the most important.”
“Do your research,” Altschuler emphasized. “It’s a relationship. Make sure you mesh as humans.”
And, keeping with the Valentine’s Day theme, Clark said, “It’s about communication. Don’t have multiple agents.”
Pasadena’s Arrowhead Pharmaceuticals, Still Buoyed by $3.7 Billion Deal, Announces New ‘Promising’ Clinical trial
Pasadena-based Arrowhead Pharmaceuticals Inc. said it has seen “promising” interim clinical results from the ongoing Phase 1/2a studies of two of its drugs based on the gene-silencing or RNAi (ribonucleic acid interference) platform.
The drugs are ARO-APOC3, being developed as a treatment for patients with severe hypertriglyceridemia, and ARO-ANG3, being developed to treat dyslipidemias and metabolic diseases.
“The interim results from the multiple-dose portion of the Phase 1 studies of Arrowhead’s cardiometabolic candidates ARO-APOC3 and ARO-ANG3 are highly encouraging and support our belief that RNAi may be the optimal mechanism to inhibit APOC3 and ANGPTL3,” Dr. Javier San Martin, Chief Medical Officer at Arrowhead, said. “We achieved high levels of APOC3 and ANGPTL3 protein knockdown, which led to impressive reductions in triglycerides and other lipid parameters. In addition, the long duration of effect of ARO-APOC3 and ARO-ANG3 enables a convenient once every four months or, possibly, once every six months dosing regimen, which also has the potential to improve patient compliance over other agents and mechanisms that require more frequent dosing.”
San Martin added there have been no drug-related discontinuations, and if there were any adverse events reported, the most common were headache, respiratory tract infections, and local injection site reactions.
“This high level of pharmacologic activity with good safety and tolerability to date is precisely what we were hoping for,” San Martin continued. “We look forward to further investigating the potential for ARO-APOC3 and ARO-ANG3 to provide clinical benefits in patients.”
Key interim results from the multiple-dose portion of the AROAPOC31001 Phase 1 clinical study of ARO-APOC3 include the following:
The tests involved severe hypertriglyceridemia patients and hypercholesterolemia patients who received varying doses of the drug candidates, and showed marked improvements such as reduced triglyceride and LDL-C (Low-density lipoprotein cholesterol) levels, among other beneficial results.
For more information, visit www.arrowheadpharma.com.